Steris plc stock dips as investors weigh valuation and recent earnings

Published on 09/19/2026 at 12:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Steris plc stock closed at USD 205.04 on the NYSE on September 18, 2026, around 8 percent below its 52-week high. The latest quarterly figures for fiscal 2026 show solid revenue growth but leave the stock trading at a rich forward multiple.

Fotorealistische Sterilisationsabteilung mit Autoklav und Instrumententabletts im Krankenhaus — Steris plc IE00BFY8C754 zeigt fotorealistisch eine moderne Krankenhaus-Sterilisationsabteilung mit Edelstahl-Autoklaven und Instrumentenwagen, Illustration mit AI erstellt.

Steris plc stock (ISIN IE00BFY8C754) closed at USD 205.04 on its NYSE listing on September 18, 2026, down USD 3.00 or 1.44 percent from the prior session according to data referenced by Nasdaq and Yahoo Finance for that trading day.

Price action and valuation signal caution

Based on the latest available closing data from September 18, 2026, Steris plc stock stood at USD 205.04 on the NYSE, with intraday indications around USD 206.35 on that date showing a decline of roughly 0.81 percent versus the previous close per price snapshots published by Reuters.

According to analyst overview data that compile recent Wall Street assessments of Steris, the shares trade at a forward price to earnings ratio of about 18.3 times based on a stock price reference of USD 207.99 and current consensus forecasts, as highlighted in a feature on favored healthcare stocks by Yahoo Finance on September 18, 2026.

Recent earnings underpin the business

For investors, the valuation debate only makes sense in the context of Steris plc’s most recently reported financial figures, which cover its latest fiscal quarter of 2026. In that quarter, Steris generated a revenue level that supports the current market capitalization in the low twenty billion USD range, with market cap indications around USD 21,000,000,000 as of September 17, 2026 referenced in earlier market data summaries.

Analyst consensus compiled in a multi-company healthcare comparison that includes Steris shows a Strong Buy stance from 18 analysts, with the average price target at USD 124.50 per share compared with a current reference level of USD 102.55 used in that overview, according to an aggregation of Wall Street views on medical technology names hosted by Perplexity finance on September 18, 2026.

Stock level versus historical range

When measured against its historical range, Steris plc stock around USD 205 to USD 208 remains below previously observed highs earlier in fiscal 2026, even as the company continues to report growing earnings and cash flow. The combination of a roughly 8 percent distance to peak levels and a forward P/E near the high teens highlights a balance between growth expectations and valuation risk for Steris plc stock as of September 18, 2026.

Closing price snapshot for Steris plc stock

As of September 18, 2026, the reference closing price for Steris plc stock on the NYSE stands at USD 205.04, with the shares having moved lower by 1.44 percent on that trading day while trading at a valuation of about 18 times forward earnings based on recent analyst estimates.